Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma

This publication has 12 references indexed in Scilit:

• Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: Preliminary results
  European Journal Of Cancer, 1993
• Editorial: Treatment for patients with hepatocellular carcinoma; state-of-the-art
  Annals of Oncology, 1992
• Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2
  European Journal of Cancer and Clinical Oncology, 1991
• Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial.
  Journal of Clinical Oncology, 1991
• Phase II trial of buserelin in hepatocellular carcinoma
  European Journal of Cancer and Clinical Oncology, 1989
• Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies
  Cancer Treatment Reviews, 1989
• Adoptive immunotherapy administered via the hepatic artery and intralesional interleukin-2 in hepatocellular carcinoma
  Cancer Treatment Reviews, 1989
• Lysis of primary hepatic tumours by lymphokine activated killer cells.
  Gut, 1987
• Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells
  Cancer, 1986
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
  The Journal of Experimental Medicine, 1982